Industrial perspective on the manufacturing of lipid nanoparticles for nucleic acid delivery
Lipid nanoparticles (LNPs) have emerged as a groundbreaking delivery platform, revolutionizing the development of nucleic acid-based medicines for gene delivery and gene therapy. This review provides an insightful industrial perspective on the production process of LNPs, focusing on cutting-edge man...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
16 April 2026
|
| In: |
Pharmaceutics
Year: 2026, Volume: 18, Fascicolo: 4, Pages: 1-29 |
| ISSN: | 1999-4923 |
| DOI: | 10.3390/pharmaceutics18040489 |
| Accesso online: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/pharmaceutics18040489 Verlag, kostenfrei, Volltext: https://www.mdpi.com/1999-4923/18/4/489 
|
| Note sull'autore: | Jenny Hong Hoang, Melanie Ott, Eleni Samaridou, Moritz Beck-Broichsitter, Johanna Simon |
| Riassunto: | Lipid nanoparticles (LNPs) have emerged as a groundbreaking delivery platform, revolutionizing the development of nucleic acid-based medicines for gene delivery and gene therapy. This review provides an insightful industrial perspective on the production process of LNPs, focusing on cutting-edge manufacturing equipment, downstream processing and the crucial transition from laboratory to large scale. While LNP production in the discovery phase relies on a small scale (& micro;L to mL) for screening various LNP formulation candidates, transferring to preclinical (up to hundreds of mL) and clinical/commercial scales (up to liters) requires a robust and reproducible manufacturing process. Thus, mixing technologies throughout these scales must be carefully selected and require precision, scalability and high reproducibility to meet the target quality of the LNP drug product. Key mixing technologies in mRNA-LNP production primarily include microfluidic systems and impinging jet mixers (IJMs). In this review, we discuss key critical process parameters (CPPs) in LNP preparation, including flow rate ratio (FRR) or total flow rate (TFR), in relation to associated critical quality attributes (CQAs) across multiple manufacturing scales. We further assess the impact of downstream processing, specifically tangential flow filtration (TFF), on the formulation's CQAs. In particular, the review highlights the importance of maintaining CQAs along each step of the process and emphasizes the role of robust analytical methods in ensuring product quality and safety. Additionally, we touch on current challenges associated with these advanced delivery vehicles, such as their long-term stability, and introduce the readership to innovative stabilization strategies aimed to extent LNP shelf-life. |
|---|---|
| Descrizione del documento: | Veröffentlicht: 16. April 2026 Gesehen am 27.07.2026 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1999-4923 |
| DOI: | 10.3390/pharmaceutics18040489 |